Tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients.

This randomized clinical trial evaluated the efficacy and safety of tumor debulking followed by chemotherapy compared with chemotherapy alone in adult patients with multiorgan metastatic colorectal cancer. The study was conducted across 27 hospitals in the Netherlands and one hospital in the UK. A total of 382 patients were randomized, with 192 assigned to chemotherapy alone and 190 assigned to chemotherapy plus tumor debulking. The median follow-up duration was 32.3 months. The primary outcome was overall survival, while secondary outcomes included progression-free survival and serious adverse events.

The primary outcome analysis revealed no improvement in overall survival for patients receiving tumor debulking. The median overall survival was 30.0 months in the chemotherapy plus tumor debulking group compared with 27.5 months in the chemotherapy alone group. The adjusted hazard ratio was 0.88, with a 95% confidence interval of 0.70 to 1.10 and a P value of .26. These results indicate that the addition of tumor debulking did not provide a statistically significant survival advantage over systemic treatment alone.

Regarding progression-free survival, the median duration was 10.5 months in the chemotherapy plus tumor debulking group versus 10.4 months in the chemotherapy alone group. The adjusted hazard ratio was 0.83, with a 95% confidence interval of 0.67 to 1.02 and a P value of .08. This finding suggests that tumor debulking also failed to delay disease progression in a clinically meaningful way compared with chemotherapy monotherapy.

Safety analysis demonstrated a concerning increase in serious adverse events in the intervention group. A total of 101 patients (53%) in the chemotherapy plus tumor debulking group experienced serious adverse events, compared with 74 patients (39%) in the chemotherapy alone group. The difference was statistically significant with a P value of .006. This higher rate of toxicity highlights the potential risks associated with adding surgical debulking to first-line palliative systemic treatment in this setting.

These findings contrast with historical expectations that cytoreductive surgery might benefit patients with extensive metastatic disease. However, the lack of survival benefit and the increased toxicity profile suggest that tumor debulking should not be routinely added to first-line palliative systemic treatment for patients with multiorgan metastatic colorectal cancer. The study limitations include the observational nature of the safety data regarding specific adverse event types, as detailed adverse event profiles were not reported beyond the aggregate serious adverse event counts. Additionally, the study did not report discontinuations due to adverse events or specific tolerability metrics.

Clinically, these results imply that physicians should not consider tumor debulking as a standard component of first-line therapy for multiorgan metastatic colorectal cancer. The data support the use of systemic chemotherapy alone as the preferred initial strategy for this population. Further questions remain regarding whether specific subgroups of patients might derive benefit from debulking, but the current evidence does not support a broad recommendation for this approach. The increased burden of serious adverse events further discourages the routine use of tumor debulking in this context.